-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Underperform on Fulcrum Therapeutics, Raises Price Target to $7

Benzinga·12/09/2025 17:54:09
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Underperform and raises the price target from $6 to $7.